GeoVax Labs Inc GOVX

US Biotechnology

$0.35 ▼ -2.58% ($-0.01)

⬇️ Below Yest. Low 🎈 Low Float 🎢 High Beta

Open $0.37

Prev Close $0.36

Day Range $0.35 – $0.38

52W Range $0.35 – $16.80

Market Cap $3.55M

Beta 3.85

EPS (TTM) $-13.92

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1994-04-04
Shares Out.	7,370,000
Website	geovax.com/ ↗
Phone	13026587581
Employees	19
Revenue	$0
Gross Profit	$0
Net Income	-$4.4M
Free Cash Flow	-$18.4M
Total Assets	$4.6M
Total Liabilities	$2.9M
Equity	$1.8M

About GeoVax Labs Inc

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

GeoVax Labs Inc is a publicly traded company under the ticker symbol GOVX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.